Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Peter Kolchinsky’s Biotech Fund Doubles Achillion Pharmaceuticals Position

RA Capital, Achillion Pharmaceuticals: In a 13G filing with the SEC, Peter Kolchinsky‘s RA Capital disclosed that it owns nearly 15% of infectious disease-focused biopharma player Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). This is an increase of nearly twofold from RA’s position last quarter, and the stock is now the largest position in his entire equity portfolio (according to 13F figures).

Peter Kolchinsky

At the end of September, Achillion said that the FDA did not remove the clinical hold on its NS3 protease inhibitor, sovaprerir, which is a part of its pipeline of therapies for the cure of chronic hepatitis C virus. “While we are disappointed that we were not able to resolve the clinical hold at this time despite having addressed all the issues, we believe the breadth of our portfolio allows us to quickly advance other all oral combination regimens for the treatment of HCV,” the President and Chief Executive Officer of Achillion, Milind Deshpande, said in a statement.

Qvt Financial, managed by Daniel Gold also owns shares of Achillion, with its stake involving almost 11 million shares of the company. James E. Flynn‘s Deerfield Management and Jerome Pfund and Michael Sjostrom‘s Sectoral Asset Management have smaller positions in the stock.

Disclosure: none

Recommended Reading:

SC Fundamental Value Calls on Transcept Pharmaceuticals to Remove Four Board Members

Russian Government Takes a 9.2% Stake in Bind Therapeutics

Broadfin Capital Opens a Stake in Celsus, Another Biotech Company Today

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!